STI571 400 mg + STI571 600 mg

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Philadelphia Positive Chronic Myeloid Leukemia

Conditions

Philadelphia Positive Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia

Trial Timeline

Aug 9, 1999 → Sep 23, 2013

NCT ID

NCT00171249

About STI571 400 mg + STI571 600 mg

STI571 400 mg + STI571 600 mg is a phase 2 stage product being developed by Novartis for Philadelphia Positive Chronic Myeloid Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00171249. Target conditions include Philadelphia Positive Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia.

What happened to similar drugs?

2 of 8 similar drugs in Philadelphia Positive Chronic Myeloid Leukemia were approved

Approved (2) Terminated (1) Active (5)

✅NilotinibNovartisApproved

✅AsciminibNovartisApproved

❌NilotinibNovartisPhase 3

🔄NilotinibNovartisPhase 3

🔄Asciminib + NilotinibNovartisPhase 3

🔄Imatinib + Nilotinib + Bosutinib + Dasatinib + AsciminibNovartisPhase 3

🔄Blinatumomab + Blinatumomab + HyperCVADAmgenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00171249	Phase 2	Completed	Aug 9, 1999	Sep 23, 2013	Philadelphia Positive Chronic Myeloid Leukemia

Competing Products

20 competing products in Philadelphia Positive Chronic Myeloid Leukemia

See all competitors

Product	Company	Stage	Hype Score
Imatinib Mesylate	Novartis	Phase 2	35
Nilotinib	Novartis	Phase 3	32
Nilotinib	Novartis	Phase 3	40
Induction Phase + Re-Induction Phase + Post-Remission + Maintenance	Novartis	Phase 2	42
nilotinib	Novartis	Phase 2	35
Asciminib + Nilotinib	Novartis	Phase 3	44
imatinib mesylate	Novartis	Phase 2	35
Blinatumomab + Asciminib	Novartis	Phase 1/2	39
Asciminib	Novartis	Phase 1	36
Asciminib Pediatric formulation group + Asciminib Adult formulation group	Novartis	Phase 1/2	39
Nilotinib + LDE225	Novartis	Phase 1	29
Nilotinib	Novartis	Approved	43
Imatinib + Nilotinib + Bosutinib + Dasatinib + Asciminib	Novartis	Phase 3	44
Asciminib	Novartis	Approved	47
Blinatumomab	Amgen	Phase 2	35
Treatment with blinatumomab given subcutaneously.	Amgen	Phase 2	42
Blinatumomab + Blinatumomab + HyperCVAD	Amgen	Phase 3	47
Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimen	Amgen	Phase 3	47
Bosutinib	Pfizer	Phase 1/2	36
Bosutinib + Bosutinib	Pfizer	Phase 1	29